^
    Back
    Association details:
    Biomarker:SLC9A2 overexpression
    Cancer:Breast Cancer
    Drug:tamoxifen (Estrogen receptor antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    SABCS 2023
    Title:

    High expression of SLC9A2 is correlation with lymphatic metastasis and poor survival in breast cancer

    Published date:
    12/02/2023
    Excerpt:
    In patients with tamoxifen therapy, SLC9A2 high expression also had poor survival comparing to low expression (HR=2.86 [1.4-5.86], p=0.0026).